Captor Therapeutics
Captor Therapeutics is a clinical-stage biopharmaceutical company developing Targeted Protein Degradation therapeutics for cancer, autoimmune, and neurodegenerative diseases. Listed on the Warsaw Stock Exchange (CTX), it operates from Wrocław, Poland and Basel, Switzerland, with a pipeline led by MCL-1 and GSPT1/NEK7/SALL4 degraders in Phase 1 trials.
- Company typePublic
- Founded2015
- HeadquartersWroclaw, Poland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Captor Therapeutics does
Captor Therapeutics S.A. is a clinical-stage biopharmaceutical company that leverages Targeted Protein Degradation (TPD) technology to develop therapeutics for cancer, autoimmune diseases, and neurodegenerative conditions. The company operates from dual headquarters in Wrocław, Poland (registered office) and Allschwil, Switzerland (European headquarters), and has been listed on the Warsaw Stock Exchange (ticker: CTX) since April 2021. Its core technology is the proprietary Optigrade™ drug discovery platform, which integrates protein engineering, structural biology, molecular modelling, and CRISPR/Cas9 genome editing to enable structure-guided design and rapid identification of degrader molecules against previously undruggable targets.
The product portfolio comprises multiple preclinical and clinical-stage degrader candidates, headlined by the MCL-1 Degrader (CT-03) in Phase Ia/Ib for hematological malignancies and the GSPT1/NEK7/SALL4 Triple Degrader (CT-02) in Phase 1 for hepatocellular carcinoma. Additional programs include brain-penetrant and systemic NEK7 degraders for neurodegeneration and autoimmunity, a PKCθ degrader for immunology and oncology, and the LiLis research platform exploring novel E3 ligases. Reported preclinical outcomes include near-100% target protein degradation in non-human primates, cardio-safe profiles for the MCL-1 program, and synergy with everolimus in HCC xenograft models.
The company is pre-revenue, with a revenue model oriented toward future licensing agreements, co-development partnerships, and ultimately commercialization of approved drug candidates. Capital sources include public equity raises on the Warsaw Stock Exchange (PLN 149.9 million at 2021 IPO; PLN ~66 million Series Y in March 2026), non-dilutive grants from the European Innovation Council (EIC/EIC Accelerator), NCBiR, and Poland's Medical Research Agency, plus research collaborations such as the November 2025 agreements with MD Anderson Cancer Center and an unnamed U.S. public pharmaceutical company. Reported 9-month net loss of PLN 32 million through September 2025 reflects ongoing R&D investment. Ownership is dispersed, with co-founder/CSO Michał Walczak holding 14.42% of share capital.
Captor Therapeutics firmographics
Firmographics- Name
- Captor Therapeutics
- Legal name
- Captor Therapeutics S.A.
- Website
- https://captortherapeutics.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Captor Therapeutics is a clinical-stage biopharmaceutical company developing Targeted Protein Degradation therapeutics for cancer, autoimmune, and neurodegenerative diseases. Listed on the Warsaw Stock Exchange (CTX), it operates from Wrocław, Poland and Basel, Switzerland, with a pipeline led by MCL-1 and GSPT1/NEK7/SALL4 degraders in Phase 1 trials.
- Ownership category
- akta.pro rank
Captor Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics (Targeted Protein Degradation)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Captor Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Wroclaw
- HQ country
- Poland
- HQ region
- Europe
Offices2 records
Markets served
Captor Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Therapeutic Development and Commercialization: Captor Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapeutics. As a pre-revenue company, it does not currently have commercialized products. The company generates revenue through potential licensing agreements, co-development partnerships, and ultimately through commercialization of its drug candidates upon regulatory approval.
- Research Grants and Non-Dilutive Funding: The company receives funding from public sources including the European Innovation Council (EIC), European Innovation Council Fund, National Centre for Research and Development (NCBiR), Medical Research Agency, and EIC Accelerator programs for specific R&D projects.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Captor Therapeutics product offering
Product offeringCore offering
Captor Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics for cancer, autoimmune, and neurodegenerative diseases. Its core offering centers on the proprietary Optigrade™ drug discovery platform and a pipeline of degrader drug candidates — including MCL-1 Degrader (CT-03), GSPT1/NEK7/SALL4 Triple Degrader (CT-02), NEK7 degraders, and PKCθ degraders — designed to eliminate disease-driving proteins that traditional small-molecule inhibitors cannot address.
Product overview
Captor Therapeutics is a biopharmaceutical company leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough therapeutics. The company's integrated offering centers on the Optigrade™ Platform, a proprietary drug discovery engine that combines protein engineering, structural biology, and molecular modeling. The product portfolio includes multiple drug candidates in clinical development: the MCL-1 Degrader (CT-03) in Phase Ia/Ib for hematological malignancies, the GSPT1/NEK7/SALL4 Triple Degramer (CT-02) for hepatocellular carcinoma in Phase I trials, NEK7 Degraders for neuroinflammation and autoimmunity, PKCθ Degrader for immunology/oncology, and the LiLis Platform exploring new E3 ligases for TPD. The company operates from Basel, Switzerland and Wrocław, Poland.
Differentiator
Problem solved
Functional benefit
Products and services
- Optigrade™ Platform Proprietary drug discovery engine integrating protein engineering, structural biology, and molecular modelling that enables structure-guided optimization of lead compound series for targeted protein degradation and rapid identification of lead-quality molecules through optimal target-ligase pair selection.
- MCL-1 Degrader (CT-03) Bifunctional MCL-1 degrader for hematological malignancies and solid tumors. It is a highly potent, cardio-safe degrader that induces apoptosis in cancer cells by eliminating MCL-1 protein (both anti-apoptotic and DNA damage response functions) and overcomes venetoclax resistance in AML. Near-complete MCL-1 protein degradation has been demonstrated in non-human primates without cardiotoxicity markers.
- GSPT1/NEK7/SALL4 Triple Degrader (CT-02) Triple degrader targeting GSPT-1, NEK7, and SALL4 proteins for treatment of hepatocellular carcinoma. Pro-drug with enhanced tissue specificity for liver and lung, demonstrating high anti-tumor activity in cell line-derived and patient-derived xenograft models and strong synergy with everolimus.
- NEK7 Degrader (Brain-Penetrant) Brain-penetrant molecular glue degrader of NEK7 for treatment of neurodegenerative diseases including Parkinson's Disease, Alzheimer's Disease, ALS, and Huntington's Disease. Capable of crossing the blood-brain barrier and achieving near 100% protein degradation in non-human primates.
- NEK7 Degrader (Systemic) Systemic molecular glue degrader targeting NEK7 for autoimmune diseases including inflammatory bowel disease (IBD), gout, and dermatological diseases. Characterized by excellent PK properties ensuring long-lasting exposure.
- PKCθ Degrader Bifunctional degrader of the active form of PKCθ for applications in autoimmunity, oncology, transplantology, and metabolism. Highly selective within the PKC family and the entire kinome (KinomeScan test), and leads to 100% PKCθ degradation in mouse models of acute immune response.
- LiLis Platform (Degraders on New E3 Ligases) Research platform harnessing new E3 ligases for targeted protein degradation. Extends the range of molecular targets addressable through TPD by utilizing novel E3 ligase-recruiting molecules.
Quantifiable outcome
- Near 100% NEK7 protein degradation in non-human primates (Macaca fascicularis) for over 20 hours after oral dosing
- +4 more outcomes
Companies that use Captor Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Captor Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Captor Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and former.
- The University of Texas MD Anderson Cancer CentermajorMemorandum of Understanding signed for collaboration in cancer research and development. MD Anderson is one of the world's most respected cancer centers, providing potential for significant scientific and clinical advancement of Captor's therapeutic candidates.
- U.S. Public Pharmaceutical CompanymajorResearch Collaboration and License Option Agreement signed with a U.S. public pharmaceutical company for development of therapeutic candidates.
- ICON Clinical Research LimitedmajorService contracts concluded for Phase I clinical trials for the CT-01 project (hepatocellular carcinoma). ICON is a leading CRO providing clinical development services.
- Ono Pharmaceutical Co., Ltd.formerCollaboration agreement signed for development of therapeutic candidates. The collaboration was subsequently terminated in March 2025 as reported in current report RB ESPI 19/2025.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Captor Therapeutics competitors and assessment
Company assessmentDirect peers
- Arvinas: Arvinas is a clinical-stage biotechnology company pioneering PROTAC targeted protein degradation for cancer and other diseases. It is the most direct public comparable to Captor, with similar platform technology, clinical-stage oncology degraders, and a comparable BD/licensing commercial model.
- Foghorn Therapeutics: Foghorn is a clinical-stage oncology biotech using a chromatin-based target-discovery engine to develop precision medicines. Comparable to Captor in scale, clinical maturity (Phase I), and platform-based approach to expanding the druggable target universe in oncology.
- C4 Therapeutics: C4 Therapeutics is a clinical-stage biotech developing degrader-based medicines (including MonoDAC and BiDAC platforms) for cancer and other diseases. Direct competitor to Captor in protein degradation technology with overlapping target selection and clinical-stage maturity.
- Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing molecular glue degraders for cancer and autoimmune diseases. It is a closely comparable peer to Captor in degrader class (molecular glues vs Captor's bifunctional degraders), disease focus, and clinical stage.
- Kymera Therapeutics: Kymera is a clinical-stage biopharmaceutical company developing targeted protein degraders across immunology-inflammation and oncology. It is directly comparable to Captor in modality (TPD), stage (Phase I/II), and disease focus (cancer and immune-mediated diseases).
Emerging players
- BioTheryX: BioTheryX is a biotechnology company developing targeted protein degraders (molecular glues and bifunctional degraders) for cancer and inflammatory diseases. Comparable to Captor as a TPD-focused peer with overlapping modality and disease strategy, though earlier-stage.
- Cullinan Oncology: Cullinan Oncology is a clinical-stage biopharmaceutical company focused on oncology with a diversified pipeline of development candidates. Comparable to Captor in size, clinical maturity, and oncology-focused pipeline strategy, though using a broader modality mix (not TPD-only).
- Amphista Therapeutics: Amphista is a European biotechnology company developing next-generation targeted protein degradation therapies leveraging novel mechanisms beyond CRBN. Comparable to Captor as a TPD platform peer focused on differentiated E3 ligase biology, with overlapping technology positioning though earlier-stage.
Broad incumbents
- Novartis: Novartis is a global pharmaceutical company with internal targeted protein degradation capabilities (including acquired programs) and a major oncology franchise. It is a relevant incumbent peer given its overlapping TPD investments and its position as a likely strategic partner/acquirer for Captor-type assets.
- Pfizer: Pfizer is a global pharmaceutical company with an active internal protein degradation effort (including via the Arvinas-partnered ARV-471) and broad oncology/immunology franchises. It is a relevant incumbent peer because of its deep TPD R&D footprint and frequent role as a major-player BD counterparty in the degrader space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Captor Therapeutics social profiles
Digital presenceCaptor Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Captor Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Captor Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Captor Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Captor Therapeutics
What does Captor Therapeutics do?
Captor Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics for cancer, autoimmune, and neurodegenerative diseases. Its core offering centers on the proprietary Optigrade™ drug discovery platform and a pipeline of degrader drug candidates — including MCL-1 Degrader (CT-03), GSPT1/NEK7/SALL4 Triple Degrader (CT-02), NEK7 degraders, and PKCθ degraders — designed to eliminate disease-driving proteins that traditional small-molecule inhibitors cannot address.
Is Captor Therapeutics a public or private company?
Captor Therapeutics is a public company. It is classified as public and is currently operating.
When was Captor Therapeutics founded?
Captor Therapeutics was founded in 2015. It employs 51 to 100 people.
Where is Captor Therapeutics based?
Captor Therapeutics is headquartered in Wroclaw, Poland, in the Europe region.
How does Captor Therapeutics make money?
Two revenue lines are on record. Therapeutic Development and Commercialization is the primary driver. The others are research Grants and Non-Dilutive Funding.
Who are Captor Therapeutics's main competitors?
Direct peers on record are Arvinas, Foghorn Therapeutics, C4 Therapeutics, Monte Rosa Therapeutics and Kymera Therapeutics. Emerging players are BioTheryX, Cullinan Oncology and Amphista Therapeutics. Broad incumbents are Novartis and Pfizer.
Does Captor Therapeutics have an API?
No public API is recorded for Captor Therapeutics.
What industry is Captor Therapeutics in?
Captor Therapeutics's product category is Biopharmaceutical Therapeutics (Targeted Protein Degradation). Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.